Observational studyFrontiers in endocrinology2026
Bone marrow cellular profile in patients with diabetes: association of statin therapy with CD34+ cells.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: Diabetes is associated with alterations in bone marrow (BM) cellularity beyond its acute and chronic complications in both type 1 and type 2 diabetes. These changes may be amplified in patients with advanced disease, such as CLTI. Key alterations include imbalance of the BM microenvironment and shifts in hematopoietic cell populations, particularly the CD34+ subpopulation. Methods: This retrospective observational study analyzed patients treated with autologous cell therapy (ACT) for chronic limb-threatening ischemia over 16 years. Patients on immunosuppressive therapy or corticoids, with stage 4-5 chronic kidney disease, repeated ACT were excluded. Harvested BM underwent hematological analysis (leucocytes, monocytes, lymphocytes) and immunophenotyping (percentage and absolute count of CD34). Outcomes were evaluated in relation to diabetes parameters (type, duration, glycated hemoglobin, diabetic complications score index - DCSI) and medications (oral antidiabetics, statins). Wilcoxon rank test and Spearman correlation were used. Results: Seventy-four patients were included from 167 in the ACT database. Statin therapy was significantly associated with higher CD34 percentage (β = 0.256, p< 0.001), while simultaneously being associated with lower lymphocyte counts, suggesting that statins may modify BM cellular composition rather than directly increase absolute progenitor cell numbers. Conclusion: Statins appear to optimize the BM microenvironment rather than increase absolute hematopoietic cell numbers in a non-hematological diabetic population with severe limb ischemia. In addition, higher DCSI scores were associated with increased CD34+ cell percentage, suggesting a link between diabetes severity and BM cellular composition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.